Last updated 2026-07-20
- Raised $43M Series B led by Sands Capital, Oct 2021
- Raised $68.5M Series A led by Forbion Capital Partners, May 2020
- Raised $11M B Round Extension led by Sands Capital, Mar 2022
Total raised
$144.5M
Last: Undisclosed Round 2022-04
Stage
Series B
Founded
2018
Headcount
61
HQ
Herzliya, Israel
Sector
Health Tech & Life Sciences
About
Prilenia Therapeutics is a late clinical-stage biotechnology company focused on developing novel therapeutics to address the progression of neurodegenerative diseases and neurodevelopmental disorders. The company's lead compound is pridopidine, a first-in-class, oral, highly selective and potent investigational S1R agonist. Pridopidine is in pre-registration for Huntington's disease (HD) and Phase 3-stage development for amyotrophic lateral sclerosis (ALS). Prilenia holds Orphan Drug designation for pridopidine in HD and ALS in the U.S. and EU, and Fast Track designation by the U.S. FDA for the treatment of HD. Prilenia operates across the United States, Canada, Europe and Israel. The company is incorporated in the Netherlands and backed by leading life sciences investors.
Funding history · 4 rounds · $144.5M total
2022-03
B Round Extension
$11.0M
★ Sands Capital★ Amplitude Ventures★ SV Health Investors★ Forbion Capital Partners★ Talisman Capital Partners★ Sectoral Asset Management★ Morningside Venture Investments
2021-10
B Round
$43.0M
★ Sands Capital★ Amplitude Ventures★ ALS Investment Fund★ Forbion Capital Partners★ Talisman Capital Partners★ Sectoral Asset Management★ Morningside Venture Investments
2020-05
A Round
$68.5M
★ Forbion Capital PartnersSectoral Asset ManagementTalisman Capital PartnersMorningside Venture Investments
2018-04
Seed
$22.0M
Headcount over time
From 3 (2019-10) to 58 (2025-12) · +55 (+1833%) · 39 points · source: Finder history + radar grounding
Q&A
- What is Prilenia Therapeutics' primary focus?
- Prilenia Therapeutics is a late clinical-stage biotechnology company focused on developing novel therapeutics to address the progression of neurodegenerative diseases and neurodevelopmental disorders, specifically Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).
- What is Prilenia Therapeutics' lead compound?
- Prilenia Therapeutics' lead compound is pridopidine (45 mg twice daily), an oral, highly selective, and potent investigational S1R agonist. It is in pre-registration for Huntington's disease (HD) and Phase 3-stage development for amyotrophic lateral sclerosis (ALS).
- Has pridopidine received any special designations?
- Yes, pridopidine holds Orphan Drug designation for Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS) in the U.S. and EU. Additionally, it has received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of HD.
- When was Prilenia Therapeutics founded?
- Prilenia Therapeutics was founded in May 2018.
- What is the total amount of funding Prilenia Therapeutics has raised?
- Prilenia Therapeutics has raised a total of $144,500,000 USD.
- When was Prilenia Therapeutics' most recent funding round and how much was raised?
- Prilenia Therapeutics' most recent funding round occurred in April 2022, raising $11,000,000 USD.
- Which investors participated in Prilenia Therapeutics' June 2020 funding round?
- The June 2020 funding round included Forbion Capital Partners.
- How many employees does Prilenia Therapeutics have?
- Prilenia Therapeutics has 51–200 employees.
- Where are Prilenia Therapeutics' offices located?
- Prilenia Therapeutics has offices in Yakum, Israel; Naarden, Netherlands; and Waltham, MA, USA.
Team · 1
Michael R. Hayden
Founder · Founder & CEO
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
drug-developmentpharmaceuticalsneurologyamyotrophic-lateral-sclerosis-alsbiotechnologyparkinsondegenerative-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | prilenia.com |
|---|---|
| linkedin.com/company/26568559 |
Identifiers & details
| Legal name | Prilenia Therapeutics B.V. |
|---|---|
| Founded | 2018-9 |
| Employees (exact) | 61 |
| Offices | Naarden; Waltham |
Radar intelligence
Open jobs — lever
| Total open | 3 |
|---|---|
| Remote | 0 |
| By department | Quality (1), Medical Affairs (1), Clinical Operations (1) |
| By location | Boston, MA (3) |
| Title | Location | Department |
|---|---|---|
| Director / Senior Director, GCP Quality Assurance Lead (US/IL/EU) | Boston, MA | Quality |
| Medical Science Liaison – Neurodegeneration (United States) | Boston, MA | Medical Affairs |
| Regional Clinical Trial Manager - East Coast, US | Boston, MA | Clinical Operations |
Patents
| EPO | 12 |
|---|
Web history (Wayback)
| Domain | prilenia.com |
|---|
Certificate / subdomain footprint
| Subdomains | 4 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515842854 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2018-05-08 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 2 — annual_report (1), people (1) |
| Registered address | 1 יקום |
Recent registry events
| Date | Event |
|---|---|
| 2026-01-19 | דו~ח שנתי-הוספת בעל תפקיד |
| 2026-01-14 | עדכון בעלי תפקידים |